Survival impact of surgical management of localized prostate cancer
The introduction of serum PSA in the late 1980s led to an abrupt increase in the incidence of prostate cancer in the United States (US). To this end, annual increases of 17.5% were noted from 1988 to 1992. [1] [2] [3] [4] [5] Although there was an annual decline of 10.3% from 1992 to 1995 since 1995 the incidence of prostate cancer has essentially leveled off. 4, 5 However, the latest data indicate that since the late 1990s there has been a slight increase in the incidence of prostate cancer, albeit at a slower rate than that seen in the early 1990s. 1 On a similar note, the pioneering work by Walsh and Donker, 6 which has improved the surgeon's ability to remove all tumors and substantially reduce perioperative morbidity, resulted in a dramatic increase in the number of radical prostatectomies performed in the US over the past 20 y (peaking at 104 000 in 1992-1993). 7 Conversely, mortality from prostate cancer has been steadily decreasing since the early 1990s (approximately a decade after the introduction of improved surgical techniques by Walsh and Donker 6 ). 5 A number of factors could have contributed to the decline in prostate cancer mortality including changing risk factors, attribution bias, earlier detection of prostate cancer with PSA testing, and changing treatment patterns prior to the PSA era.
Changing risk factors
A decline in the initiation of prostate cancer or the risk of progression of prostate cancer as a result of a change in the risk factors that initiate or promote the disease could lead to a decline in mortality. For example, in 1971, Herbst et al 8 described an increased risk for clear cell adenocarcinoma of the vagina in young women with in utero exposure to diethylstilbestrol (DES). However, changing risk factors most often affect disease in birth cohorts to different degrees 9 whereas prostate cancer mortality declined for all birth cohorts. Thus, a change in risk factors is not a likely explanation for declining prostate cancer mortality.
Attribution bias
Some men who die of other causes with a diagnosis of prostate cancer have their deaths misattributed to prostate cancer. 10, 11 If there are a fixed proportion of deaths that are misattributed in the population and the number of men with a diagnosis of prostate cancer increases, then one might expect prostate cancer mortality to mirror incidence. Thus, the initial decline in mortality that occurred after the peak in prostate cancer incidence may have been due in part to misattribution of deaths. But the continuing decline in mortality may not be.
PSA testing
None would argue that the widespread use of PSA has led to a dramatic increase in the incidence of prostate cancer and an increase in the incidence of early stage disease. Could the detection and treatment of early stage disease with PSA screening be a factor in the mortality decline? If this were the case, we should expect an inverse relationship between the intensity of screening and mortality. However, Perron et al 12 have shown that there is no relationship between the intensity of PSA testing and changes in mortality among 15 different birth cohorts and 15 different regions in Canada. In addition, prostate cancer mortality rates in England and Wales show similar trends to the US despite the lack of widespread screening in England and Wales. 13 These data suggest that PSA screening and the successful treatment of early prostate cancer was not responsible for mortality declines seen to date.
Surgical management of localized prostate cancer
It is difficult to determine whether the decrease in deaths from prostate cancer is related to the increase in the number of radical prostatectomies performed over the past two decades. However, it is important to note that between 1983 and 1991, the proportion of men aged 60-79 y treated surgically for prostate cancer increased rapidly and it is men from this age group who also experienced the greatest decline in mortality due to prostate cancer (which was lower in 1997 than it had been in any year since 1950). 7, 14, 15 Whether radical prostatectomy provides any survival benefit for men with localized prostate cancer has recently been addressed by Holmberg et al. 16 The study revealed that 8.9% of men in the expectant management group and 4.6% in the radical prostatectomy group died from prostate cancer (P ¼ 0.02). In addition, there was a 14% absolute reduction in the rate of development of distant metastases in the radical prostatectomy group compared with the expectant management group.
The landmark study by Holmberg et al 16 implies that PSA screening resulting in early detection and treatment may produce survival benefit. Although this is yet to be proven, the same group recently updated their study and determined that after a median follow-up of 8 y, 8.6 vs 14.4% of men assigned to either surgery or watchfulwaiting, respectively, died from prostate cancer. 17 Furthermore, the authors reported that the difference in the cumulative incidence of death due to prostate cancer is 5.3% after 10 y. 17 Hopefully, further light on this subject will be shed by the Prostate Cancer Intervention vs Observation Trial (PIVOT), 18, 19 which is a multicenter, randomized prospective study that aims to determine the optimal therapy for localized prostate cancer by randomizing to either radical prostatectomy with early intervention for disease persistence/recurrence vs expectant management with palliative therapy reserved for symptomatic or metastatic disease progression. Unlike the study by Holmberg et al 16 the PIVOT study consists of a PSA screened cohort, and thereby, more closely resembles those detected with prostate cancer today in the USA. It is hoped that the results of PIVOT will be available in 2010.
Over diagnosis with prostate cancer screening
The widespread utilization of serum PSA has led, not only to an increase in the incidence of prostate cancer, but also to a profound stage migration of prostate cancer at diagnosis. As such, the majority of men diagnosed today is solely due to an elevated serum PSA level (stage T1c). 5 This has fuelled the argument that many of these cancers are of low volume and pose little threat to life, and that PSA screening has led to prostate cancer over diagnosis. To this end, Etzioni et al 20 have recently estimated that approximately 30% of screen detected cancers are over diagnosed. These data are consistent with findings from radical prostatectomy series that show that about 20-30% of cancers are small volume lower grade and potentially harmless. 21, 22 Over diagnosis has contributed to the increased popularity of expectant management of this disease over the past 5-7 y.
Studies examining the impact of expectant management in localized prostate cancer
One of the earliest studies investigating the natural history of localized prostate cancer was conducted by Johansson et al 23, 24 who assessed disease progression and survival in 223 patients (mean age 72 y) in a populationbased (Orebro county, Sweden) study. The authors demonstrated that the 5-and 10-year disease-specific survival and the overall progression-free survival were similar to comparably aged men without prostate cancer. Similar results have been shown by Jones 25 and Whitmore and Warner. 26 The above studies, despite their limitations, provided evidence that older patients with localized, small volume, low-grade disease may be safely managed expectantly. To this end, European urologists have adopted expectant management of localized prostate cancer over the past decade. Such a management approach in the US had initially received little attention. However, subsequent studies by Albertsen et al 27, 28 and Johansson et al 29 helped to change this attitude and raise the enthusiasm for expectant management of localized prostate cancer in the US.
Albertsen et al 27 reported that after a mean follow-up of 15.5 y, the age-adjusted survival for men with Gleason score 2-4 tumors was not significantly different from those of the general population. However, the maximum estimated lost life expectancy for men with Gleason score 5-7 and 8-10 tumors was 4-5 and 6-8 y, respectively. Therefore, conservatively treated older men with lowgrade prostate cancer incur no loss of life expectancy compared with the general population. (Table 1) respectivley. This study has recently been updated and the authors reported very similar findings with men harboring low-grade prostate cancers (Gleason score 2-4) having a minimal risk of dying from prostate cancer (6/ 1000 person-years) after a median follow-up of 24 y. 30 On the other hand, men with high-grade prostate cancer (Gleason scores 8-10) have a high probability of dying within 10 y of diagnosis (121/1000 person-years). 30 However, it should be noted that these patients were diagnosed prior to the PSA era. Hence, when relating these data to contemporary patients we should consider the PSA screening associated lead-time bias. Therefore, small volume Gleason score 6 and 7 disease are likely to exhibit significantly lower long-term mortality rates in contemporary patients and may not warrant early active therapy. Johansson et al 29 have published similar longterm (15-year) follow-up results and concluded that patients with localized prostate cancer can be safely managed expectantly and that an aggressive approach to all patients with early disease would entail substantial over treatment. However, these authors recently reported that prostate cancer mortality rate increased from 15/ 1000 person-years during the first 15 y to 44/1000 person-years beyond 15 y of follow-up. 31 They concluded from this that those presenting with clinically localized prostate cancer and have a life expectancy 415 y should be considered for early radical treatment. A possible reason for the differences in the finding between this study and that of Albertsen et al 30 is that in this study prostate cancer was diagnosed by aspiration biopsy and classified according to the World Health Organization grading system, whereas in the study by Albertsen et al 30 the Gleason grading system was used. Therefore, it is feasible that the differences in classification between the two systems, especially amongst the moderately differentiated group, might have partly accounted for the different long-term survival data. Furthermore, deaths from prostate cancer were determined using different methods. Namely, Johansson et al 31 relied on the review of medical records. However, in the study by Albertsen et al 30 death certificates were used to the determine cause of death. Therefore, misclassification of the cause of death in these two studies might also have partly accounted for the different long-term survival data.
Expectant management
MA Khan and AW Partin Albertsen et al 28 subsequently confirmed their previous findings in a separate long-term study which revealed that men managed expectantly with Gleason score 2-4 disease had only a 4-7% chance of dying from prostate cancer, whereas this figure was 6-70% and 60-87% for Gleason score 5-7 and 8-10 disease
Evaluation of patients suitable for expectant management
Clinically localized prostate cancer exhibits tremendous heterogeneity in its activity. To this end, studies investigating expectant management of this disease clearly shows that a significant percent will exhibit either local or distant progression with time. [23] [24] [25] [26] [27] [28] [29] Therefore, in an attempt to more accurately predict patients that harbor clinically insignificant disease and are likely to fair well with expectant management, Epstein et al 21 examined preoperative clinical and pathologic parameters in men with stage T1c disease who underwent radical prostatectomy. The authors correlated these findings with the pathologic extent of disease in the surgical specimen and demonstrated that 16% of the T1c tumors were insignificant (o0.2 cm 3 and confined to the prostate with Gleason score o7). Furthermore, the best model for predicting insignificant tumor was PSA density o0.1 ng/ml/g and no adverse pathologic findings on needle biopsy or a PSA density of 0.1-0.15 ng/ ml/g with a low-to intermediate-grade cancer smaller than 3 mm found in only one needle biopsy core specimen. Using this model Epstein et al 21 accurately predicted 73% of cases with insignificant tumor. Carter et al 32 further determined the ability of pre-treatment parameters, as described by Epstein et al 21 (ie PSA density X0.15 ng/ml/g or Gleason score X7 or X3 cores involved with cancer or X50% involvement of any core with cancer), to predict tumor significance in men with stage T1c disease. The authors reported that the percent of insignificant cases that underwent surgery remained stable (16 vs 17%) 32 (Table 2) . Therefore, using pretreatment criteria it is possible to minimize the number of patients who will receive active treatment for insignificant tumor. In addition, Epstein et al 33 recently demonstrated that tumor dedifferentiation does not occur over 2-3 y. Hence, men treated expectantly can be reassured that there is little evidence that cancer grade worsens during the short term.
Carter et al 34 have also shown that men who go on to develop aggressive prostate cancer have significantly 
Impact of delayed intervention in men initially managed expectantly
Choo et al 35 recently assessed in a prospective study whether it is feasible to initially manage men expectantly and then instigate active treatment in the presence of disease progression (PSA doubling time p2 y or grade progression on re-biopsy). The authors determined that the estimated actuarial probability of remaining progression-free with expectant management was 81 and 67% at 2 and 4 y, respectively. The same group recently published their updated study and determined that at 8 y the overall actuarial survival is 85% and diseasespecific survival 99%. 36 They, therefore, concluded that it is feasible to conduct a policy of expectant management with selectively delayed intervention. In this way, men with indolent disease may avoid active therapy while definitive therapy can be provided for those with biologically active disease.
Carter et al 37 evaluated the strategy of expectant management for men with stage T1c disease which consisted of semiannual PSA and digital rectal examination and annual prostate biopsies. Recommendation for treatment was made if disease progression was indicated by unfavorable follow-up needle biopsy findings (ie Gleason grade X4, 42 cores positive for cancer, or 450% involvement of any core with cancer). They observed that 92% of men who underwent radical prostatectomy for disease progression had curable cancers. The authors, therefore, concluded that expectant management with curative intent might be a reasonable alternative for carefully selected older men with small volume cancers.
Quality of life after active or expectant management
Quality of life outcomes is an important issue that needs to be taken into account when patients are offered different treatment modalities to address localized prostate cancer. This subject has recently been addressed by Steineck et al 38 who evaluated symptoms and selfassessments of quality of life in the same group of men participating in a randomized comparison study between radical prostatectomy and expectant management, as reported by Holmberg et al. 16 The results demonstrated that erectile dysfunction (80 vs 45%) and urinary incontinence (49 vs 21%) were more common, whereas urinary obstruction (28 vs 44%) was less common, after surgery. Bowel function, prevalence of anxiety and depression, well-being, and subjective quality of life were similar in the two groups. Therefore, although expectant management and prostatectomy entail different risks, it has little influence on well-being or the subjective quality of life.
It is important to note that in the study by Steineck et al, 38 nerve-sparing surgery was not routinely performed. In addition, many were 465 y and 28% received hormonal therapy during follow-up. Furthermore, the majority had palpable diseases. Hence, these factors may account for the high prevalence of ED and urinary incontinence experienced in these men compared with contemporary US patients undergoing radical prostatectomy. 39 Nevertheless, it is interesting that despite experiencing higher prevalence of ED and urinary incontinence radical prostatectomy did not adversely affect the patients' well-being or subjective quality of life compared with expectant management. This may, in part, be related to the higher urinary obstructive symptoms experienced by men managed expectantly.
Conclusion
Expectant management of localized prostate cancer has evolved over the past decade. Using pathologic and clinical parameters it is possible to safely manage patients in this manner. Elderly men or men with significant co-morbidities, such that life expectancy is o10 y, should be considered for expectant management with palliative intervention if they become symptomatic. However, younger, healthier men with low-grade, lowvolume disease may be considered for curative therapy in the presence of disease progression during follow-up.
